News
Boehringer announces IPF deal with Korea's Bridge Biotherape...
Boehringer Ingelheim and South Korean biotech Bridge Biotherapeutics have announced a deal to develop the latter’s drug for idiopathic pulmonary fibrosis (IPF).
